References
- Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21(1):18–26.
- Koratala A, Singhania G, Alquadan KF, et al. Serum uric acid exhibits inverse relationship with estimated glomerular filtration rate. Nephron. 2016;134(4):231–237.
- Darmon M, Vincent F, Camous L, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162(4):489–497.
- Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics. 2008;2(1):129–141.
- Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–4213.
- Mayne N, Keady S, Thacker M. Rasburicase in the prevention and treatment of tumour lysis syndrome. Intensive Crit Care Nurs. 2008;24(1):59–62.
- Tamura K, Kawai Y, Kiguchi T, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016;21(5):996–1003.
- Sood AR, Burry LD, Cheng DK. Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy. 2007;27(1):111–121.
- Bose P, Qubaiah O. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. J Clin Pharm Ther. 2011;36(3):299–326.
- Lopez-Olivo MA, Pratt G, Palla SL, et al. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(3):481–492.
- Canet E, Cheminant M, Zafrani L, et al. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome? Leuk Lymphoma. 2014;55(10):2362–2367.
- Martens KL, Khalighi PR, Li S, et al. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020;89:106298.
- May HP, Mara KC, Barreto EF, Leung N, Habermann TM. Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. Leuk Lymphoma. 2021;25:1–8.